Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) FCF Margin: 2009-2025

Historic FCF Margin for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to -31.42%.

  • China Pharma Holdings' FCF Margin fell 2799.00% to -31.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.03%, marking a year-over-year increase of 1606.00%. This contributed to the annual value of -11.89% for FY2024, which is 174.00% down from last year.
  • China Pharma Holdings' FCF Margin amounted to -31.42% in Q3 2025, which was down 209.88% from 28.60% recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' FCF Margin peaked at 52.11% during Q3 2023, and registered a low of -72.04% during Q1 2023.
  • For the 3-year period, China Pharma Holdings' FCF Margin averaged around -8.31%, with its median value being -7.86% (2024).
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by 5,955bps in 2022, then surged by 5,381bps in 2023.
  • Over the past 5 years, China Pharma Holdings' FCF Margin (Quarterly) stood at -7.10% in 2021, then soared by 2,805bps to 20.95% in 2022, then tumbled by 2,220bps to -1.25% in 2023, then surged by 1,759bps to 16.34% in 2024, then slumped by 2,799bps to -31.42% in 2025.
  • Its last three reported values are -31.42% in Q3 2025, 28.60% for Q2 2025, and -10.41% during Q1 2025.